Kiniksa Pharmaceuticals, Ltd.KNSANASDAQ
LOADING
|||
Switch Symbol:
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +67.37% | +46.93% | +72.54% | +44.34% | +61.17% |
| Gross Profit Growth | +58.39% | -0.48% | +57.55% | +29.60% | +54.88% |
| EBITDA Growth | +0.00% | -717.24% | +0.00% | +6455.27% | +0.00% |
| Operating Income Growth | +0.00% | -23925.93% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | -135.22% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | -133.33% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | -134.29% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +2.20% | +2.77% | +2.85% | +3.43% | +2.62% |
| Weighted Average Shares Diluted Growth | +2.20% | -0.47% | +7.80% | +9.77% | +8.78% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -113.16% | +333.99% | +459.92% | +443.54% | +0.00% |
| Free Cash Flow Growth | -113.18% | +335.16% | +469.43% | +440.34% | +0.00% |
| Receivables Growth | +718.41% | +96.20% | +150.48% | +56.03% | +107.90% |
| Inventory Growth | +12.11% | -15.29% | -19.10% | +38.22% | +44.34% |
| Asset Growth | +14.95% | +10.30% | +15.33% | +21.89% | +28.28% |
| Book Value per Share Growth | +5.55% | -2.78% | +2.99% | +10.00% | +19.38% |
| Debt Growth | -18.27% | -19.60% | -18.35% | -14.36% | -8.28% |
| R&D Expense Growth | +54.97% | +77.27% | -26.18% | -21.53% | -7.36% |
| SG&A Expenses Growth | +37.43% | +10.33% | +12.53% | +10.54% | +5.83% |